Shenzhen Hornetcorn Bio-technology Company, LTD
11
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect
Role: lead
Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis
Role: lead
D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)
Role: lead
Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela
Role: lead
Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer
Role: lead
DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma
Role: lead
Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer
Role: lead
Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis
Role: lead
Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis
Role: lead
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
Role: lead
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
Role: lead
All 11 trials loaded